Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurological Sciences
Erschienen in: Neurological Sciences 10/2021

12.07.2021 | Review Article

LncRNAs as putative biomarkers and therapeutic targets for Parkinson’s disease

verfasst von: Eskandar Taghizadeh, Seyed Mohammad Gheibihayat, Forough Taheri, Seyed Mohammadreza Afshani, Najmeh Farahani, Alihossein Saberi

Erschienen in: Neurological Sciences | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is known as one of the most common degenerative disorders related to the damage of the central nervous system (CNS). This brain disorder is also characterized by the formation of Lewy bodies in the cytoplasm of the dopaminergic neurons in the substantia nigra pars compacta (SNc), which consequently leads to motor and non-motor symptoms. With regard to the growing trend in the number of cases with PD and its effects on individuals, families, and communities, immediate treatments together with diagnostic methods are required. In this respect, long non-coding ribonucleic acids (lncRNAs) represent a large class of ncRNAs with more than 200 nucleotides in length, playing key roles in some important processes including gene expression, cell differentiation, genomic imprinting, apoptosis, and cell cycle. They are highly expressed in the CNS and previous studies have further reported that the expression profile of lncRNAs is disrupted in human diseases such as neurodegenerative disorders. Since the levels of some lncRNAs change over time in the brains of patients with PD, a number of previous studies have examined their potentials as biomarkers for this brain disorder. Therefore, the main purpose of this study was to review the advances in the related literature on lncRNAs as diagnostic, therapeutic, and prognostic biomarkers for PD.
Literatur
1.
Pringsheim T, Jette N, Frolkis A, Steeves T (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis
2.
Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 51:35PubMedCrossRef
3.
Bonifati V (2014) Genetics of Parkinson’s disease–state of the art, 2013. Parkinsonism Relat Disord 20:S23PubMedCrossRef
4.
Renani P, Taheri F, Rostami D, Farahani N, Abdolkarimi H, Abdollahi E et al (2019) Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson’s disease and epigenetic-based therapies. J Cell Physiol 234(11):19307PubMedCrossRef
5.
Bradaric BD, Patel A, Schneider JA, Carvey PM, Hendey B (2012) Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm 119(1):59CrossRef
6.
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368PubMedCrossRef
7.
Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y et al (2015) The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47(3):199PubMedPubMedCentralCrossRef
8.
9.
Quinn J, Chang H (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17(1):47PubMedCrossRef
10.
Managadze D, Lobkovsky AE, Wolf YI, Shabalina SA, Rogozin IB, Koonin EV (2013) The vast, conserved mammalian lincRNome. PLoS Comput Bio. 9(2).
11.
Qureshi IA, Mehler MF (2013) Long non-coding RNAs: novel targets for nervous system disease diagnosis and therapy. Neurotherapeutics 10(4):632–646PubMedPubMedCentralCrossRef
12.
Kadakkuzha BM, Liu X-A, McCrate J, Shankar G, Rizzo V, Afinogenova A, et al. (2015) Transcriptome analyses of adult mouse brain reveal enrichment of lncRNAs in specific brain regions and neuronal populations. Front Cell Neurosci; 9
13.
Ponjavic J, Oliver PL, Lunter G, Ponting CP (2009) Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain. PLoS Genet;5(8):e1000617-e.
14.
Zhou Y, Gu C, Li J, Zhu L, Huang G, Dai J et al (2018) Aberrantly expressed long noncoding RNAs and genes in Parkinson’s disease. Neuropsychiatr Dis Treat 14:3219PubMedPubMedCentralCrossRef
15.
Qureshi IA, Mehler MF. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat rev Neurosci 13(8):528
16.
17.
Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6(6):309–317PubMedCrossRef
18.
Bonanni L, Thomas A, Onofrj M (2006) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 66(9):1455 (author reply)
19.
Kraus T, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretzschmar H (2017) Altered long noncoding RNA expression precedes the course of Parkinson’s disease-a preliminary report. Mol Neurobiol 54(4):2869PubMedCrossRef
20.
Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, et al. (2014) Long non-coding RNA and alternative splicing modulations in Parkinson’s leukocytes identified by RNA sequencing. PLoS Comput Bio 10(3)
21.
Lv Q, Wang Z, Zhong Z, Huang W (2020) Role of long noncoding RNAs in Parkinson’s disease: putative biomarkers and therapeutic targets. Parkinson’s Disease 2020
22.
You J, Fang N, Gu J, Zhang Y, Li X, Zu L et al (2014) Noncoding RNA small nucleolar RNA host gene 1 promote cell proliferation in nonsmall cell lung cancer. Indian Journal cancer. 51:e99
23.
Hall J, Messenger Z, Tam H, Phillips S, Recio L, Smart R (2015) Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death & Dis. 6(3):e1700
24.
Zou J, Guo Y, Wei L, Yu F, Yu B, Xu A (2020) Long noncoding RNA POU3F3 and α-synuclein in plasma L1CAM exosomes combined with β-glucocerebrosidase activity: potential predictors of Parkinson’s disease. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics
25.
Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C et al (2014) Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 128(5):639PubMedPubMedCentralCrossRef
26.
Lv Q, Wang Z, Zhong Z, Huang W (2020) Role of long noncoding RNAs in Parkinson’s disease: putative biomarkers and therapeutic targets. Parkinson’s Disease 2020
27.
Jamebozorgi K, Taghizadeh E, Rostami D, Pormasoumi H, Barreto G, Hayat S et al (2019) Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives. Mol Neurobiol 56(7):4799PubMedCrossRef
28.
Fonseca-Ornelas L, Eisbach S, Paulat M, Giller K, Fernández C, Outeiro T et al (2014) Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun 5:5857PubMedCrossRef
29.
Chen Y, Lian Y, Ma Y, Wu C, Zheng Y, Xie N (2018) LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells. Neurotoxicology 68:212PubMedCrossRef
30.
Chaturvedi RK, Flint BM (2013) Mitochondrial diseases of the brain. Free Radical Biol Med 63:1–29CrossRef
31.
Ni Y, Huang H, Chen Y, Cao M, Zhou H, Zhang Y (2017) Investigation of long non-coding RNA expression profiles in the substantia nigra of Parkinson’s disease. Cell Mol Neurobiol 37(2):329–338PubMedCrossRef
32.
Ni Y, Huang H, Chen Y, Cao M, Zhou H, Zhang Y (2017) Investigation of long non-coding RNA expression profiles in the substantia nigra of Parkinson’s disease. Cell Mol Neurobiol 37(2):329PubMedCrossRef
33.
Wen J, Ma Y, Yang G, Wang G (2017) Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma. Eur Rev Med Pharmacol Sci 21(3):498PubMed
34.
Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X et al (2012) Long non-coding RNA UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 41(1):276PubMed
35.
Lu M, Sun W, Shen J, Wei M, Chen B, Qi Y et al (2018) LncRNA-UCA1 promotes PD development by upregulating SNCA. Eur Rev Med Pharmacol Sci 22(22):7908PubMed
36.
Cai L, Tu L, Li T, Yang X, Ren Y, Gu R et al (2019) Downregulation of lncRNA UCA1 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson’s disease through the inhibition of the PI3K/Akt signaling pathway. Int immunopharmacology. 75:105734
37.
Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y et al (2009) Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson’s disease. Proc Natl Acad Sci USA 106(12):4635PubMedPubMedCentralCrossRef
38.
Grimes D, Han F, Panisset M, Racacho L, Xiao F, Zou R et al (2006) Translated mutation in the Nurr1 gene as a cause for Parkinson’s disease. Mov dis: offic J Mov Dis Soc 21(7):906
39.
Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A et al (2006) Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell 126(4):775–788PubMedCrossRef
40.
Gong B, Cao Z, Zheng P, Vitolo O, Liu S, Staniszewski A et al (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126(4):775PubMedCrossRef
41.
Carrieri C, Forrest AR, Santoro C, Persichetti F, Carninci P, Zucchelli S, et al (2015) Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells’ differentiation in vitro and in neurochemical models of Parkinson’s disease. Front Cell Neurosci 9
42.
Riva P, Ratti A, Venturin M (2016) The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res 13(11):1219PubMedCrossRef
43.
Li Y, Fang J, Zhou Z, Zhou Q, Sun S, Jin Z, et al (2020) Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson’s disease by upregulating microRNA-34b-5p and downregulating BACE1. Cell Cycle (Georgetown, Tex) 1–14
44.
Scrivo A, Bourdenx M, Pampliega O, Cuervo AM (2018) Selective autophagy as a potential therapeutic target for neurodegenerative disorders. Lancet Neurol 17(9):802
45.
Tanida I, Ueno T, Kominami E (2008) LC3 and Autophagy. Methods in molecular biology (Clifton, NJ) 445:77CrossRef
46.
Xie S, Zhou F, Li J, Duan S (2019) NEAT1 regulates MPP+-induced neuronal injury by targeting miR-124 in neuroblastoma cells. Neurosci lett. 708:134340
47.
Simchovitz A, Hanan M, Niederhoffer N, Madrer N, Yayon N, Bennett ER et al (2019) NEAT1 is overexpressed in Parkinson’s disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. FASEB J 33(10):11223–11234PubMedPubMedCentralCrossRef
48.
Yan W, Chen Z, Chen J, Chen H (2018) LncRNA NEAT1 promotes autophagy in MPTP-induced Parkinson’s disease through stabilizing PINK1 protein. Biochem Biophys Res Commun 496(4):1019PubMedCrossRef
49.
Kawajiri S, Saiki S, Sato S, Sato F, Hatano T, Eguchi H et al (2010) PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett 584(6):1073PubMedCrossRef
50.
Li L, Xu J, Wu M, Hu J (2018) Protective role of microRNA-221 in Parkinson’s disease. Bratisl Lek Listy 119(1):22PubMed
51.
Geng L, Zhao J, Liu W, Chen Y (2019) Knockdown of NEAT1 ameliorated MPP+-induced neuronal damage by sponging miR-221 in SH-SY5Y cells. RSC Adv 9(43):25257–25265CrossRefPubMedPubMedCentral
52.
Xu X, Cui L, Zhong W, Cai Y (2020) Autophagy-associated lncRNAs: promising targets for neurological disease diagnosis and therapy. Neural Plast
53.
Boros F, Maszlag-Török R, Vécsei L, Klivényi P (2020) Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease. Brain res. 1730:146672
54.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ et al (2010) Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291):1071PubMedPubMedCentralCrossRef
55.
Liu S, Cui B, Dai Z, Shi P, Wang Z, Guo Y (2016) Long non-coding RNA HOTAIR promotes Parkinson’s disease induced by MPTP through up-regulating the expression of LRRK2. Curr Neurovasc Res 13(2):115PubMedCrossRef
56.
Zhou F, Xie S, Li J, Duan S (2019) Long noncoding RNA HOTAIR promotes cell apoptosis by sponging miR-221 in Parkinson’s disease. RSC Adv 9(51):29502–29510CrossRefPubMedPubMedCentral
57.
Lang Y, Li Y, Yu H, Lin L, Chen X, Wang S et al (2020) HOTAIR drives autophagy in midbrain dopaminergic neurons in the substantia nigra compacta in a mouse model of Parkinson’s disease by elevating NPTX2 via miR-221-3p binding. Aging (Albany NY) 12(9):7660CrossRef
58.
Zhang Q, Huang X-M, Liao J-X, Dong Y-K, Zhu J-L, He C-C, et al. LncRNA HOTAIR promotes neuronal damage through facilitating NLRP3 mediated-pyroptosis activation in Parkinson’s disease via regulation of miR-326/ELAVL1 axis. Cell mol neurobiol.
59.
Lin Q, Hou S, Dai Y, Jiang N, Lin Y (2019) LncRNA HOTAIR targets miR-126-5p to promote the progression of Parkinson’s disease through RAB3IP. Biol Chem 400(9):1217PubMedCrossRef
60.
Yang L, Zhang X, Li H, Liu J (2016) The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma. Mol BioSyst 12(8):2605PubMedCrossRef
61.
Zhang Q, Huang X-M, Liao J-X, Dong Y-K, Zhu J-L, He C-C, et al. (2020) LncRNA HOTAIR promotes neuronal damage through facilitating NLRP3 mediated-pyroptosis activation in Parkinson’s disease via regulation of miR-326/ELAVL1 axis. Cellular and Molecular Neurobiology:1–14
62.
Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z et al (2010) A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J 29(18):3082PubMedPubMedCentralCrossRef
63.
Bennett M (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105(3):311PubMedCrossRef
64.
Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S et al (2015) Targeting α-synuclein for treating Parkinson’s disease: mechanistic and therapeutic considerations. The Lancet Neurology 14(8):855PubMedPubMedCentralCrossRef
65.
Cai L-J, Tu L, Huang X-M, Huang J, Qiu N, Xie G-H et al (2020) LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease. Mol Brain 13(1):130PubMedPubMedCentralCrossRef
66.
Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, et al. (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. NPJ Parkinson’s Disease 3
67.
Gureev A, Popov V (2019) Nrf2/ARE pathway as a therapeutic target for the treatment of Parkinson diseases. Neurochem Res 44(10):2273PubMedCrossRef
68.
Okorji U, Velagapudi R, El-Bakoush A, Fiebich B, Olajide O (2016) Antimalarial drug artemether inhibits neuroinflammation in BV2 microglia through Nrf2-dependent mechanisms. Mol Neurobiol 53(9):6426PubMedCrossRef
69.
Chen Q, Huang X, Li R (2018) lncRNA MALAT1/miR-205-5p axis regulates MPP+-induced cell apoptosis in MN9D cells by directly targeting LRRK2. Am J Trans Res 10(2):563
70.
Esteves AR, Swerdlow RH, Cardoso SM (2014) LRRK2, a puzzling protein: insights into Parkinson’s disease pathogenesis. Experimental neurology 206
71.
Imai Y, Gehrke S, Wang H-Q, Takahashi R, Hasegawa K, Oota E et al (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27(18):2432PubMedPubMedCentralCrossRef
72.
Lee B, Shin J, VanKampen J, Petrucelli L, West A, Ko H et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med 16(9):998PubMedPubMedCentralCrossRef
73.
Liu W, Zhang Q, Zhang J, Pan W, Zhao J, Xu Y (2017) Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease. Cell & Bioscience 7
74.
Majidinia M, Mihanfar A, Rahbarghazi R, Nourazarian A, Bagca B, Avci ÇB (2016) The roles of non-coding RNAs in Parkinson’s disease. Mol Biol Rep 43(11):1193–1204PubMedCrossRef
Metadaten
Titel
LncRNAs as putative biomarkers and therapeutic targets for Parkinson’s disease
verfasst von
Eskandar Taghizadeh
Seyed Mohammad Gheibihayat
Forough Taheri
Seyed Mohammadreza Afshani
Najmeh Farahani
Alihossein Saberi
Publikationsdatum
12.07.2021
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 10/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05408-7

Weitere Artikel der Ausgabe 10/2021

Neurological Sciences 10/2021 Zur Ausgabe

Letter to the Editor

Roussy-Lévy syndrome: a case of genotype–phenotype correlation

Review Article

Advances in hyperekplexia and other startle syndromes

COVID-19

Predictors of survival in older adults hospitalized with COVID-19

Original Article

A retrospective observation on 105 patients with chronic cluster headache receiving indomethacin

Original Article

Clinical manifestations and polysomnography-based analysis in nine cases of probable sporadic Creutzfeldt-Jakob disease

Original Article

Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Frühe Alzheimertherapie lohnt sich

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise